ALR Technologies to Host Investor Meeting Discussing Diabetes Management Technology

ALR Technologies, Inc. (OTCBB:ALRT) is hosting an investor meeting/webinar after the markets close on Monday, March 19, 2012 at 4:30 PM EDT.  CEO and Chairman Sidney S. Chan will be providing an investor presentation to discuss corporate developments and product launch as well as conducting a question and answer session about the company and its Health-e-Connect (HeC) system for chronic disease management.  ALR Technologies received FDA 510(k) marketing clearance for their HeC system as a new solution for diabetes management in the fourth quarter of 2011.

Seating for the meeting is limited, so investors are encouraged to register below and add the date to their calendars to learn more about this exciting company.

ALR Technologies (ALRT) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

JP Morgan: The Re-Education of Ina

JP Morgan: The Re-Education of Ina(0)

Many Wall Street Veterans have taken this path at some point in their careers, it comes with the volatile territory they ply…and Ina Drew …..Head Risk Honcho…. at JP Morgan & Chase (NYSE: JPM) is no different than the countless number of Wall St execs who have climbed the mountain and literally fell down the

Fibrocell Submits Phase II Protocol for Burn Scars Treatment to FDA

Fibrocell Submits Phase II Protocol for Burn Scars Treatment to FDA(0)

Fibrocell Science, Inc. (OTCBB: FCSC), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced this morning that is has submitted to the U.S. Food & Drug Administration (FDA) the company’s Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell’s lead therapy,

KMA Global Solutions Stock Chart Analysis Video

KMA Global Solutions Stock Chart Analysis Video(0)

After a monster move from $0.0005 to $0.0231, shares of KMA Global International (Pink Sheets: KMAG) have seen some profit taking. Ending last week with two green closes, technical traders will be watching for a potential continuation of a bounce off support at $0.006. Technically speaking, it is important for the chart to hold these

Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug

Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0)

Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug.  The

FDA to Expedite the Drug Approval Process for Breakthroughs

FDA to Expedite the Drug Approval Process for Breakthroughs(0)

An article released yesterday by Reuters titled, “U.S. may speed approval of ‘breakthrough’ drugs” could prove extremely valuable for biotechs of all sizes.  According to the article, Experimental drugs that show a big effect early in development for treating serious or life-threatening diseases would get a faster and cheaper path to U.S. approval, under a

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.